Role of Iron Therapy in Heart Failure: A Consensus Statement from India.

H K Chopra, G S Wander,Tiny Nair, C K Ponde, Navin C Nanda,Jagat Narula,Saumitra Ray, K Venugopal, S S Iyengar, R R Kasliwal,Praveen Chandra, Sunil Prakash, Sandeep Bansal, D S Rana,Prafulla Kerkar, Arup Dasbiswas,Jps Sawhney, S Shanmungasundram, Viveka Kumar, I B Vijayalakshmi,A K Pancholia, Vinod Sharma,Aditya Kapoor,Onkar C Swami, H S Isser, Vishal Rastogi, Y K Arora, Ashok K Omar, Sunil Sathe, Rajeeve Rajput, D Prabhakar, G J Paul,Priya Jagia, Poonam Malhotra, G Suryaprakash, Vinod Mittal, Manish Jagia, A Jabir, S S Mishra, S N Routray, Ajay K Sinha, Mohan Bhargava, Kiran Mahmood, Mona Bhatia, Pramila Kalra, V K Katyal,Rohit Tandon, Rahul Grover, Abhinav Chhabra, N R Shastry

The Journal of the Association of Physicians of India（2023）

引用 0|浏览1

暂无评分

摘要

Iron deficiency (ID) with or without anemia is frequently observed in patients with heart failure (HF). Uncorrected ID is associated with higher hospitalization and mortality in patients with acute HF (AHF) and chronic HF (CHF). Hence, in addition to chronic renal insufficiency, anemia, and diabetes, ID appears as a novel comorbidity and a treatment target of CHF. Intravenous (IV) ferric carboxymaltose (FCM) reduces the hospitalization risk due to HF worsening and improves functional capacity and quality of life (QOL) in HF patients. The current consensus document provides criteria, an expert opinion on the diagnosis of ID in HF, patient profiles for IV FCM, and correct administration and monitoring of such patients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要